English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Aim: To assess the calcium homeostasis after treatment with denosumab in women with non metastatic breast cancer Patients and Methods: We prospectively enrolled 42 female patients with osteoporosis, who were eligible for treatment with denosumab. Patients were divided in two groups. In Group A were included 24 healthy postmenopausal women (controls) and in group B were included 18 patients with non metastatic breast cancer. A single-dose of denosumab (60mg) was administered to both groups, under standard calcium and vitamin D supplementation. Serum calcium, phosphorus, parathyroid hormone (iPTH) and 24hr urine calcium were measured at days 0, 7 and 180. Primary outcomes were the development of hypocalcaemia and secondary hyperparathyroidism. Results: At baseline, both groups were comparable in age, calcium and iPTH levels. No events of hypocalcaemia were recorded. Overall, incidence of secondary hyperparathyroidism was found to be 45.5% one week after administration of denosumab At day 7, iPTH was found to be significantly higher only in controls (Wilcoxon Signed Rank test: p = 0.013) compared to group-specific baseline values. Interestingly, at day 180 incidence of secondary hyperparathyroidism was higher in Group B in contrast to the pattern recorded in controls, although not reaching statistical significance. At day 180, borderline increase in iPTH of Group B was noted (p = 0.08), whereas iPTH returned to baseline in controls. Conclusions: A pattern of delayed development of secondary hyperparathyroidism might be present in patients with non-metastatic breast cancer. It could be extrapolated that this finding might be associated with a partial functional defect in calcium sensing receptor, which has recently been implicated in the pathogenesis of breast cancer. The findings warrant further investigation. Group A Group B

Calcium homeostasis in women with non-metastatic breast cancer with osteoporosis after a single dose of denosumab: a pilot study